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338FIG. 1. Influence of proinflammatory cytokines on
metabolic changes in joint tissues.
TNFÆ, tumor necrosis factor alpha; IL-1, interleukin-1;
MMP, metalladependent metalloproteinases; HA,
hyaluronan.MOLECULAR marker is a molecule whose concen-
ration in a body fluid (joint fluid, blood or urine)
rovides a measure of a specific metabolic process
ccurring in a joint [1]. Markers are beginning to
elp shed light on disease processes by enabling
cientists to ask questions that could not be
ddressed until now. Recent research in the field of
steoarthritis has been relatively successful in
dentifying and developing the potential of
olecular markers whose concentrations in joint
uid and serum provide critical information con-
erning the state of health of joint tissues,
specially articular cartilage. Measurement of the
evel of a marker in joint fluid (undiluted synovial
uid or joint fluid lavage) should be used when the
rimary goal is to identify changes taking place in
single joint [1, 2]. As cartilaginous structures in
ynovial joints make up only a minor proportion of
he total mass of cartilage in the body, the level
f a cartilage-derived molecular marker in blood
r urine is most useful to identify systemic changes
#ecting the metabolism of matrix constituents
n all or most cartilaginous structures in the body
1, 2].
Osteoarthritis, a condition that a#ects the
ajority of individuals over the age of 55, can only
e detected clinically during the late stages of the
isease. At that time, the articular surfaces within
he a#ected joint are so severely eroded that the
nly remedial treatment lies in replacing the joint
ith an artificial implant. The development of
ensitive immunoassays capable of detecting
roducts of the degradation or synthesis of
olecules that play key functional roles in joint
issues has raised the hope that one may soon be
ble to detect osteoarthritis at a much earlier
tage [1, 2].
Keratan sulfate is a major constituent of the
ggrecan molecules which give articular cartilage
ts ability to function as a shock absorber.
easurement of its concentration in serum is
ost e#ective in identifying abnormal metabolic
rocesses occurring in a knee joint following atraumatic injury that predisposes to osteoarthritis
[1]. Studies of this and other markers have begun
to suggest that many deleterious changes do occur
during the first few days after such an injury [1, 2].
Importantly, the results are providing important
new information that is being used to develop new
forms of therapies for the early treatment of sports
injuries.
Recent studies also have demonstrated that
measurement of certain markers in serum are most
e#ective in determining whether a new drug is
e#ective in slowing down the deleterious processes
or promoting repair of articular cartilage in
patients with joint disease [1, 3]. This represents a
major breakthrough that should help researchers
in their goal to develop more e#ective drugs to
combat the disease.
The most significant development during the
past few years has been the identification of two
serum markers (hyaluronan and cartilage-
oligomeric matrix protein) with prognostic value.
In a retrospective study, for example, OA patients
with the highest levels of hyaluronan in serum
showed the most rapid rate of joint destruction
Osteoarthritis and Cartilage Vol. 7 No. 3 339over the next five years [4]. We postulate here that
this rise in HA in serum probably is related to the
appearance of increased levels of proinflammatory
cytokines (i.e. TNFÆ and/or IL-1) which have two
key deleterious e#ects upon the matrix of articular
chondrocytes (Fig. 1), i.e. suppression of repair
processes and promotion of matrix degradation.
The identification of these ‘prognostic markers’
may soon enable clinicians to select individuals
most likely to develop severe joint destruction for
more aggressive forms of treatment.References
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